Seres Therapeutics (MCRB) Total Liabilities (2016 - 2025)
Historic Total Liabilities for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $99.8 million.
- Seres Therapeutics' Total Liabilities fell 3555.48% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year decrease of 3555.48%. This contributed to the annual value of $126.0 million for FY2024, which is 6876.34% down from last year.
- Per Seres Therapeutics' latest filing, its Total Liabilities stood at $99.8 million for Q3 2025, which was down 3555.48% from $110.8 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Total Liabilities ranged from a high of $408.8 million in Q2 2024 and a low of $99.8 million during Q3 2025
- Over the past 5 years, Seres Therapeutics' median Total Liabilities value was $238.9 million (recorded in 2022), while the average stood at $249.9 million.
- In the last 5 years, Seres Therapeutics' Total Liabilities soared by 5671.25% in 2023 and then tumbled by 7288.44% in 2025.
- Quarter analysis of 5 years shows Seres Therapeutics' Total Liabilities stood at $223.4 million in 2021, then soared by 51.33% to $338.0 million in 2022, then increased by 19.37% to $403.5 million in 2023, then crashed by 68.76% to $126.0 million in 2024, then decreased by 20.83% to $99.8 million in 2025.
- Its Total Liabilities stands at $99.8 million for Q3 2025, versus $110.8 million for Q2 2025 and $113.7 million for Q1 2025.